Atrium Therapeutics, Inc.
RNA Nasdaq
SEC CIK 2093101
Follow Atrium Therapeutics
Weekly email: filings, results
Revenue, last quarter
$15.3M
+24.2% vs same quarter last year
Net income
−$4.3M
−11429.7% vs same quarter last year
EPS, diluted
−$0.25
Operating cash flow
−$25.4M
−2339% vs same quarter last year
Source: SEC XBRL filings · latest filing